Biogen To Build New Gene Therapy Facility With $200M Investment

by Vandana Singh, Benzinga Editor

March 4, 2021 12:24 PM | 1 min read | Make a Comment

Biogen Inc (NASDAQ: BIIB) plans to build a new gene therapy manufacturing facility at its Research Triangle Park manufacturing campuses in North Carolina to support its growing gene therapy pipeline, with an estimated total investment of approximately $200 million.
Biogen aims to continue its investment in North Carolina through the new facility and expand its existing operations and a combined workforce of approximately 1,900 employees at both campuses in Research Triangle Park.
The new 175,000 square feet facility will create approximately 90 new jobs and be operational by 2023.
Price Action: BIIB shares are up 0.3% at $267.33 in market trading hours on the last check Thursday.

Posted In: Biotech News Health Care FDA General

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.